ATE202099T1 - Quinoxalindion-nmda rezeptorantagonisten - Google Patents

Quinoxalindion-nmda rezeptorantagonisten

Info

Publication number
ATE202099T1
ATE202099T1 AT95931989T AT95931989T ATE202099T1 AT E202099 T1 ATE202099 T1 AT E202099T1 AT 95931989 T AT95931989 T AT 95931989T AT 95931989 T AT95931989 T AT 95931989T AT E202099 T1 ATE202099 T1 AT E202099T1
Authority
AT
Austria
Prior art keywords
pct
alkyl
group
date mar
ch2ch3
Prior art date
Application number
AT95931989T
Other languages
English (en)
Inventor
Charles Eric Mowbray
Alan Stobie
David John Bull
Christopher Lee Carr
Michael Johnathan Fray
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Application granted granted Critical
Publication of ATE202099T1 publication Critical patent/ATE202099T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT95931989T 1994-09-13 1995-09-01 Quinoxalindion-nmda rezeptorantagonisten ATE202099T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9418443A GB9418443D0 (en) 1994-09-13 1994-09-13 Therapeutic agents
PCT/EP1995/003483 WO1996008485A1 (en) 1994-09-13 1995-09-01 Quinoxalinedione nmda receptor antagonists

Publications (1)

Publication Number Publication Date
ATE202099T1 true ATE202099T1 (de) 2001-06-15

Family

ID=10761258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95931989T ATE202099T1 (de) 1994-09-13 1995-09-01 Quinoxalindion-nmda rezeptorantagonisten

Country Status (14)

Country Link
US (1) US5783572A (de)
EP (1) EP0781279B1 (de)
JP (1) JP2898097B2 (de)
AT (1) ATE202099T1 (de)
CA (1) CA2199845C (de)
DE (1) DE69521323T2 (de)
DK (1) DK0781279T3 (de)
ES (1) ES2158126T3 (de)
FI (1) FI113471B (de)
GB (1) GB9418443D0 (de)
GR (1) GR3036270T3 (de)
MX (1) MX9701894A (de)
PT (1) PT781279E (de)
WO (1) WO1996008485A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5874426A (en) * 1995-06-07 1999-02-23 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9605027D0 (en) 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones
WO1998023599A1 (en) * 1996-11-25 1998-06-04 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
TW526195B (en) 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
DE19936521A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate
WO2002072542A2 (en) * 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
EP2481408A3 (de) 2007-03-01 2013-01-09 Probiodrug AG Neue Verwendung von Inhibitoren der Glutaminyl Cyclase
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CN103058957A (zh) 2007-06-29 2013-04-24 埃莫里大学 用于神经保护的nmda受体拮抗剂
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EA201390876A1 (ru) * 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
DE102015011861B4 (de) * 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
WO1994000124A1 (en) * 1992-06-22 1994-01-06 Eckard Weber Glycine receptor antagonists and the use thereof

Also Published As

Publication number Publication date
EP0781279A1 (de) 1997-07-02
PT781279E (pt) 2001-09-28
JPH09511523A (ja) 1997-11-18
FI971026A0 (fi) 1997-03-12
CA2199845C (en) 2000-08-01
DE69521323D1 (de) 2001-07-19
US5783572A (en) 1998-07-21
FI113471B (fi) 2004-04-30
DK0781279T3 (da) 2001-09-03
GB9418443D0 (en) 1994-11-02
GR3036270T3 (en) 2001-10-31
CA2199845A1 (en) 1996-03-21
EP0781279B1 (de) 2001-06-13
ES2158126T3 (es) 2001-09-01
FI971026A7 (fi) 1997-03-12
JP2898097B2 (ja) 1999-05-31
WO1996008485A1 (en) 1996-03-21
DE69521323T2 (de) 2001-09-20
MX9701894A (es) 1997-06-28

Similar Documents

Publication Publication Date Title
DE69521323D1 (de) Quinoxalindion-nmda rezeptorantagonisten
FI942187A0 (fi) Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
DE69225500D1 (de) Chinazolinone als mittel gegen angina
DE69409525D1 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
NZ508910A (en) Di-substituted piperazine or piperidine derivatives useful as muscarinic antagonists
ATE225780T1 (de) Biphenylderivate, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel
FI962753L (fi) Menetelmä lääkeaineena käytt¦kelpoisen piperidyyli- tai pyrrolidiinijohdannaisen tai sen farmaseuttisen suolan valmistamiseksi
PT100620A (pt) Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
ATE131479T1 (de) 1,3-dihydro-2h-imidano 4,5-b-quinolin-2-ein derivate als phosphodiestenase hemmer
GR3017648T3 (en) Use of (omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl)1H-azole derivatives for the preparation of medicines for the treatment of troubles of the capability of knowing functions.
DE69733478D1 (de) Ether-muskarinantagonisten
ATE147071T1 (de) 1,4-disubstituierte piperidinderivate, ihre herstellung und therapeutische verwendung
NZ333513A (en) 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
GB9000301D0 (en) Piperidine & pyrrolidine derivatives
DE69210647D1 (de) 1,2,4-Triazolo[1,5-a]pyrimidinderivate, Verfahren zu ihrer Herstellung, diese enthaltende Arzneimittel und ihre Verwendung
ATE144509T1 (de) Imidazolylmethyl-pyridine
DE69430068D1 (de) Benzodiazepinderivate
DK0461012T3 (da) Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse
TNSN00037A1 (fr) 1,2,3,4-tetrahydro-1-naphtalenamines nouvelles, procede pour leur preparation, et compositions pharmaceutiques les contenant
TH9795A (th) 1-(1h-อิมิดาซอล-4-อิล)อัลคิลเบนซามีตที่ถูกแทนที่
TH21210A (th) วิธียับยั้งผลของแอมิลอยโดเอนิค โปรตีน
UY24465A1 (es) Antagonistas oxadiazol y tiadiazol del receptor muscarinico

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee